Positive results for Moderna’s next-gen COVID-19 vaccine

26 March 2024

US mRNA specialist Moderna (Nasdaq: MRNA) this morning announced that mRNA1283, its next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase III clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222 (Spikevax), Moderna's licensed COVID-19 vaccine.

"We are excited to announce our fourth infectious disease vaccine program with positive Phase III data, further validating our robust mRNA platform," said Stéphane Bancel, chief executive of Moderna. "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."

Key study findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK